# Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

> **NCT07299695** · PHASE3 · RECRUITING · sponsor: **Argyrios Tzouvelekis** · enrollment: 196 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Acute Exacerbation of Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Intravenous immunoglobulin (IVIG)
- **DRUG:** Usual treatment

## Key facts

- **NCT ID:** NCT07299695
- **Lead sponsor:** Argyrios Tzouvelekis
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-25
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07299695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07299695, "Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07299695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*